In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.
first published: Nov 9, 2015 12:36 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty reclaims 25,300, registers over 1% gain this week | Closing Bell
Live: Will Nifty bulls aim to break 25,250 after strong TCS Q2? | Opening Bell
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
